What is claimed is:

1. An isolated human monoclonal antibody or antigen-binding fragment thereof that binds human interleukin 33 (IL-33), wherein the antibody or antigen-binding fragment thereof inhibits or attenuates IL-33-mediated signaling and comprises the complementarity determining regions (CDRs) of a heavy chain variable region (HCVR) having the amino acid sequence of SEQ ID NO: 274 and the CDRs of a light chain variable region (LCVR) having the amino acid sequence of SEQ ID NO: 282.

2. The isolated antibody or antigen-binding fragment of claim 1, wherein the antibody or antigen-binding fragment thereof blocks the interaction of IL-33 and ST2.

3. The isolated antibody or antigen-binding fragment of claim 2, wherein the antibody or antigen-binding fragment thereof blocks the interaction of IL-33 and ST2 with an IC_{50} value of less than about 10 nM, or blocks greater than about 50% of the interaction of IL-33 and ST2 as measured in an *in vitro* receptor/ligand binding assay at 25ºC.

4. The isolated antibody or antigen-binding fragment of any one of claims 1 to 3, wherein the antibody or antigen-binding fragment thereof binds human IL-33 with a binding dissociation equilibrium constant (K_D) of less than about 1 nM as measured in a surface plasmon resonance assay at 37ºC.

5. The isolated antibody or antigen-binding fragment of any one of claims 1 to 4, wherein the antibody or antigen-binding fragment thereof binds human IL-33 with a dissociative half-life (t½) of greater than about 8 minutes as measured in a surface plasmon resonance assay at 37ºC.

6. The antibody or antigen-binding fragment of any one of claims 1 to 5, wherein the antibody or antigen-binding fragment thereof inhibits IL-33-mediated degranulation of human basophils.

7. The antibody or antigen-binding fragment of claim 6, wherein the antibody or antigen-binding fragment thereof inhibits IL-33-mediated degranulation of human basophils with an IC_{50} of less than about 600 pM as measured in an *in vitro* basophil activation test (BAT).

8. The antibody or antigen-binding fragment of any one of claims 1 to 7, wherein the antibody or antigen-binding fragment thereof inhibits IL-33-mediated IFN-gamma production from human PBMCs.

9. The antibody or antigen-binding fragment of claim 8, wherein the antibody or antigen-binding fragment thereof inhibits IL-33-mediated IFN-gamma production from human PBMCs with an IC_{50} of less than about 25 nM as measured in an *in vitro* PBMC IFN-gamma production assay.

10. The antibody or antigen-binding fragment of claim 9, wherein the antibody or antigen-binding fragment thereof inhibits IL-33-mediated IFN-gamma production from human PBMCs with an IC_{50} of less than about 3 nM as measured in an *in vitro* PBMC IFN-gamma production assay.

11. The antibody or antigen-binding fragment of claim 10, wherein the antibody or antigen-binding fragment thereof inhibits IL-33-mediated IFN-gamma production from human PBMCs with an IC_{50} of less than about 0.5 nM as measured in an *in vitro* PBMC IFN-gamma production assay.

12. The antibody or antigen-binding fragment of any one of claims 1 to 11, comprising HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 domains, respectively, of SEQ ID NOs: 276-278-280-284-286-288.

13. The antibody or antigen-binding fragment of claim 12, comprising the HCVR/LCVR amino acid sequence pair of SEQ ID NOs: 274/282.

14. The antibody of any one of claims 1 to 13, wherein the antibody has a human IgG1 or human IgG4 constant region.

15. An isolated nucleic acid molecule encoding an antibody or antigen-binding fragment of any of claims 1 through 14.

16. An expression vector comprising the nucleic acid molecule of claim 15.

17. A host cell comprising the expression vector of claim 16.

18. A pharmaceutical composition comprising the antibody or antigen-binding fragment of any one of claims 1 to 14, and a pharmaceutically acceptable carrier or diluent.

19. Use of an antibody or antigen-binding fragment of any one of claims 1 to 14 in the manufacture of a medicament for treating an inflammatory disease or disorder, wherein the inflammatory disease or disorder is an IL-33-mediated inflammatory disease or disorder selected from the group consisting of asthma, atopic dermatitis, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease, multiple sclerosis, arthritis, allergic rhinitis, eosinophilic esophagitis and psoriasis.

20. The use of claim 19, wherein the inflammatory disease or disorder is asthma.

21. The use of claim 20, wherein the asthma is eosinophilic or non-eosinophilic asthma.

22. The use of any of claims 19-21, wherein the asthma is steroid resistant or steroid sensitive asthma.

23. The method of claim 22, wherein the asthma includes an asthma exacerbation.

24. The use of claim 19, wherein the inflammatory disease or disorder is atopic dermatitis.

25. The use of claim 19, wherein the inflammatory disease or disorder is chronic obstructive pulmonary disease (COPD).

26. The use of claim 25, wherein the chronic obstructive pulmonary disease results from, or is caused in part by cigarette smoke.

27. Use of an antibody or antigen-binding fragment of any one of claims 1 to 14 in the manufacture of a medicament for treating a patient who demonstrates a sensitivity to an allergen.

28. The use of any of claims 19-27, wherein the medicament is for use in combination with a second therapeutic agent useful for alleviating the inflammatory disease or disorder, or for diminishing an allergic response to an allergen.

29. The use of claim 28, wherein the second therapeutic agent is selected from the group consisting of a non-steroidal anti-inflammatory (NSAID), a corticosteroid, a bronchial dilator, an antihistamine, epinephrine, a decongestant, a thymic stromal lymphopoietin (TSLP) antagonist, an IL-13 antagonist, an IL-4 antagonist, an IL-4/IL-13 dual antagonist, an IL-5 antagonist, an IL-6 antagonist, an IL-12/23 antagonist, an IL-22 antagonist, an IL-25 antagonist, an IL-17 antagonist, an IL-31 antagonist, an oral PDE4 inhibitor and another IL-33 antagonist or a different antibody to IL-33.